Ashland Inc. (ASH)

NYSE: ASH · Real-Time Price · USD

49.22

-5.17 (-9.51%)

At close: May 01, 2025, 3:39 PM

-9.51% (1D)

Bid	49.19
Market Cap	2.32B
Revenue (ttm)	1.95B
Net Income (ttm)	-125M
EPS (ttm)	-0.1
PE Ratio (ttm)	-492.15
Forward PE	10.3
Analyst	Buy

Ask	49.24
Volume	1,059,820
Avg. Volume (20D)	760,378
Open	49.25
Previous Close	54.39
Day's Range	48.62 - 50.95
52-Week Range	45.21 - 102.50
Beta	0.57

About ASH

Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives;...

[Read more]

Industry Chemicals - Specialty

Sector Basic Materials

IPO Date Mar 17, 1980

Employees 3,200

Stock Exchange NYSE

Ticker Symbol ASH

Website https://www.ashland.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for ASH stock is "Buy." The 12-month stock price forecast is $72.5, which is an increase of 47.31% from the latest price.

Stock Forecasts

Earnings Surprise

New

Ashland has released their quartely earnings on Apr 30, 2025:

Revenue of $479M misses estimates by $23.62M, with -16.70% YoY decline.

EPS of 0.99 misses estimates by -0.11, with -22.05% YoY decline.

Why Price Moved

2 hours ago New

Ashland shares are trading lower after the company... Unlock content with Pro Subscription

1 month ago

+4.9%

Ashland shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $68 to $71.

News

23 hours ago · zacks.com

Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

23 hours ago · zacks.com

Ashland (ASH) Lags Q2 Earnings and Revenue Estimates

Ashland (ASH) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.27 per share a year ago.

1 week ago · zacks.com

Earnings Preview: Ashland (ASH) Q2 Earnings Expected to Decline

Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago · zacks.com

Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil

ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.

1 month ago · zacks.com

Ashland Wraps Up Divestment of Avoca Business to Mane

ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.

2 months ago · seekingalpha.com

Ashland Presents Attractive Upside Emerging From The Downcycle

Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 mont...

2 months ago · seekingalpha.com

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are...